FY2024 EPS Estimates for The Cooper Companies, Inc. Increased by Analyst (NASDAQ:COO)

The Cooper Companies, Inc. (NASDAQ:COO) – Investment analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of Cooper Companies in a report issued on Wednesday, September 4th. William Blair analyst M. Kaczor now expects that the medical device company will post earnings of $3.65 per share for the year, up from their prior estimate of $3.57. The consensus estimate for Cooper Companies’ current full-year earnings is $3.66 per share. William Blair also issued estimates for Cooper Companies’ Q4 2024 earnings at $0.99 EPS, Q1 2025 earnings at $0.95 EPS, Q2 2025 earnings at $0.97 EPS, Q4 2025 earnings at $1.07 EPS and FY2025 earnings at $4.06 EPS.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. During the same period in the prior year, the company earned $0.84 earnings per share. The firm’s revenue was up 7.8% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the stock. Jefferies Financial Group raised shares of Cooper Companies from a “hold” rating to a “buy” rating and boosted their price target for the company from $107.00 to $115.00 in a report on Tuesday, July 16th. Wells Fargo & Company upped their target price on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Stifel Nicolaus reiterated a “buy” rating and set a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Finally, Piper Sandler increased their price objective on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $113.61.

Cooper Companies Trading Up 0.1 %

Shares of NASDAQ COO opened at $106.59 on Thursday. Cooper Companies has a 12-month low of $75.93 and a 12-month high of $107.82. The company has a market cap of $21.22 billion, a price-to-earnings ratio of 62.70, a price-to-earnings-growth ratio of 2.56 and a beta of 0.98. The company has a current ratio of 1.99, a quick ratio of 1.14 and a debt-to-equity ratio of 0.33. The stock’s 50 day simple moving average is $93.30 and its 200 day simple moving average is $94.65.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Treasurer of the State of North Carolina raised its position in Cooper Companies by 0.9% during the fourth quarter. Treasurer of the State of North Carolina now owns 22,861 shares of the medical device company’s stock valued at $8,652,000 after buying an additional 212 shares during the period. Hsbc Holdings PLC boosted its holdings in shares of Cooper Companies by 55.3% during the fourth quarter. Hsbc Holdings PLC now owns 87,718 shares of the medical device company’s stock worth $33,188,000 after purchasing an additional 31,234 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Cooper Companies during the first quarter worth approximately $2,211,000. Whittier Trust Co. grew its position in Cooper Companies by 298.9% during the first quarter. Whittier Trust Co. now owns 11,940 shares of the medical device company’s stock valued at $1,211,000 after purchasing an additional 8,947 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its stake in Cooper Companies by 43.1% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 35,233 shares of the medical device company’s stock valued at $3,076,000 after buying an additional 10,616 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Cooper Companies news, CFO Brian G. Andrews sold 24,788 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $105.90, for a total value of $2,625,049.20. Following the sale, the chief financial officer now directly owns 6,614 shares in the company, valued at $700,422.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Cooper Companies news, CFO Brian G. Andrews sold 24,788 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total value of $2,625,049.20. Following the transaction, the chief financial officer now owns 6,614 shares in the company, valued at $700,422.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total value of $12,129,356.16. Following the sale, the chief operating officer now owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. The disclosure for this sale can be found here. 2.00% of the stock is owned by corporate insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.